title: Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System.
abstract: BACKGROUND
  National statistics are presented for patient survival and graft survival in patients seropositive for the human immunodeficiency virus (HIV+) at the time of renal transplantation in the era prior to highly active antiretroviral therapy (HAART).
  
  
  METHODS
  Historical cohort analysis of 63, 210 cadaveric solitary renal transplant recipients with valid HIV serology entries in the United States Renal Data System (USRDS) from 1 January 1987 to 30 June 1997. The medical evidence form was also used for additional variables but, because of fewer available values, was analyzed in a separate model. Outcomes were patient characteristics and survival associated with HIV+ status.
  
  
  RESULTS
  Thirty-two patients (0.05%) in the study period were HIV+ at transplant. HIV+ patients were comparable to the national renal transplant population in terms of gender and ethnic distribution but were younger and had younger donors and better HLA matching than the USRDS population. Patient and graft three-year survival were significantly reduced in HIV+ recipients (53% graft, 83% patient survival) relative to the USRDS population (73% and 88%, respectively). In multivariate analysis, HIV+ status was independently associated with patient mortality and decreased graft survival in recipients of cadaveric kidney transplants.
  
  
  CONCLUSIONS
  This analysis was retrospective and may underestimate the number of HIV+ patients transplanted in the United States. Although the clinical details of patient selection for transplant were unknown, these results show HIV+ patients can have successful outcomes after cadaveric renal transplantation, although outcomes are significantly different from HIV- recipients.
authors.affiliation: Nephrology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: A D
authors.initials: AD
authors.lastname: Kirk
authors.forename: C W
authors.initials: CW
authors.lastname: Ko
authors.forename: C A
authors.initials: CA
authors.lastname: Jones
authors.forename: L Y
authors.initials: LY
authors.lastname: Agodoa
authors.forename: K C
authors.initials: KC
authors.lastname: Abbott
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002102:Cadaver; D015331:Cohort Studies; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012042:Registries; D016019:Survival Analysis; D014481:United States